LBA34 Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): Preliminary results of two independent phase II trials

D.M. O'Malley; A. Oaknin; B.J. Monk; A. Leary; F. Selle; J. Alexandre; L.M. Randall; C. Rojas; M. Neffa; A. Kryzhanivska; L. Gladieff; D. Berton; T. Meniawy; I. Lugowska; I. Bondarenko; K.N. Moore; W.I. Ortuzar Feliu; M. Ancukiewicz; I. Shapiro; I.L. Ray-Coquard

Journal ArticleOPEN ACCESS

LBA34 Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): Preliminary results of two independent phase II trials

O'Malley D
Oaknin A
Monk B
et al.

Annals of Oncology (2020) 31 S1164-S1165

DOI: 10.1016/j.annonc.2020.08.2264

N/ACitations

25Readers

Abstract

Background: Second line treatment for R/M CC continues to be a high unmet clinical need. We present data from 2 ph2 trials, of single-agent balstilimab (bal) and in combination with zalifrelimab (zal) in R/M CC.

Cite

CITATION STYLE

APA

O’Malley, D. M., Oaknin, A., Monk, B. J., Leary, A., Selle, F., Alexandre, J., … Ray-Coquard, I. L. (2020). LBA34 Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): Preliminary results of two independent phase II trials. Annals of Oncology, 31, S1164–S1165. https://doi.org/10.1016/j.annonc.2020.08.2264

LBA34 Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): Preliminary results of two independent phase II trials

Abstract

Cite

Register to see more suggestions